Humanized Liver Mice Model Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Humanized Liver Mice Model Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)


The global incidence of liver cirrhosis is on the rise, driven by various risk factors, including Hepatitis B virus (HBV), Hepatitis C virus (HCV), and liver cancer. According to global statistics, 257 million people were infected with chronic HBV in 2015, with Asia and Africa experiencing high endemic prevalence rates of over 8%. Liver cancer ranks as the 7th most common cancer worldwide, with approximately 841,080 new cases diagnosed annually, as per Glococan 2018 data.

The growing prevalence of liver cirrhosis is driving the demand for humanized liver mice models used in research studies focused on treatment and therapy development for this condition. Several key factors are contributing to the growth of the humanized liver mice model market:

Technological Advancement and Development of New Humanized Liver Mice Models

Researchers are actively working on developing new humanized liver mice models with improved reliability and consistency. Earlier models used simple immunodeficient mice implanted with human liver cells or hepatic cancer cells, but the results were inconsistent. Advancements have led to the development of immunodeficient mice that naturally replace their liver with human liver cells, resulting in more stable humanized liver mice models. Researchers are also exploring the use of PPARalpha and AFC8-based mice models, further enhancing the range of options.

Increasing Number of FDA Approvals for Hepatitis Drugs

The rising number of drug approvals, particularly for hepatitis treatments, indicates the volume of research and toxicity studies conducted using pre-clinical models like humanized liver mice. While there were only four drug approvals for hepatitis treatment from 2011 to 2014, the following three years (2015-2017) saw approximately eight approvals, highlighting the significance of these models in drug development.

High Cost of Humanized Liver Mice Models and Shipping

Despite their importance, humanized liver mice models come with a significant cost. Immunodeficient mice for liver studies range from US$140 to US$500, while chimeric humanized liver mice models with substantial human hepatocyte replacement can cost between US$2,500 and US$3,500. Additionally, specialized shipping containers and protocols add to the overall cost, making these models expensive for researchers.

Focus on 3Rs Principles

The 3Rs principles (replace, reduce, and refine) are influencing the use of animals for testing, including humanized liver mice models. These principles encourage the replacement of animal models with alternatives like 2D and 3D cell lines or lab-on-chip devices. They also emphasize reducing the number of animals used and refining experiment protocols to minimize animal suffering without compromising research outcomes.

Segmentation

The report provides an extensive categorization of the humanized liver mice model market, considering various factors such as model type, application, end-user, and geographical region. Model types encompass uPA-SCID Mice, FRG-KO Mice, TK-NOG mice, and other models. In terms of applications, the humanized liver mice model market is divided into pharmacokinetics studies, in-vivo liver toxicity testing, drug metabolism studies, and other relevant applications.

Competitive Landscape

The humanized liver mice model market features key players like Yecuris Corporation, PhoenixBio Group, Beijing Vitalstar Biotechnology Co. Ltd., Hera BioLabs, Taconic Biosciences, Inc., University of Massachusetts Medical School, Oncodesign, University of Nebraska Medical Center, and Jackson Laboratory.

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.


1. Executive Summary
1.1. Global Humanized Liver Mice Model Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Humanized Liver Mice Model Market Outlook, 2018 – 2031
3.1. Global Humanized Liver Mice Model Market Outlook, by Model, Value (US$ Mn), 2018 – 2031
3.1.1. Key Highlights
3.1.1.1. uPA-SCID
3.1.1.2. FRG KO Mice
3.1.1.3. TK-NOG Mice
3.1.1.4. Other Models
3.2. Global Humanized Liver Mice Model Market Outlook, by Application, Value (US$ Mn), 2018 – 2031
3.2.1. Key Highlights
3.2.1.1. Pharmacokinetics Studies
3.2.1.2. In-vivo Liver Toxicity Testing
3.2.1.3. Drug Metabolism Studies
3.2.1.4. Others
3.3. Global Humanized Liver Mice Model Market Outlook, by End User, Value (US$ Mn), 2018 – 2031
3.3.1. Key Highlights
3.3.1.1. Pharmaceutical Companies
3.3.1.2. Biotechnology Companies
3.3.1.3. Contract Research Organizations (CRO’s)
3.3.1.4. Academic & Research Institutes
3.4. Global Humanized Liver Mice Model Market Outlook, by Region, Value (US$ Mn), 2018 – 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Humanized Liver Mice Model Market Outlook, 2018 – 2031
4.1. North America Humanized Liver Mice Model Market Outlook, by Model, Value (US$ Mn), 2018 – 2031
4.1.1. Key Highlights
4.1.1.1. uPA-SCID
4.1.1.2. FRG KO Mice
4.1.1.3. TK-NOG Mice
4.1.1.4. Other Models
4.2. North America Humanized Liver Mice Model Market Outlook, by Application, Value (US$ Mn), 2018 – 2031
4.2.1. Key Highlights
4.2.1.1. Pharmacokinetics Studies
4.2.1.2. In-vivo Liver Toxicity Testing
4.2.1.3. Drug Metabolism Studies
4.2.1.4. Others
4.3. North America Humanized Liver Mice Model Market Outlook, by End User, Value (US$ Mn), 2018 – 2031
4.3.1. Key Highlights
4.3.1.1. Pharmaceutical Companies
4.3.1.2. Biotechnology Companies
4.3.1.3. Contract Research Organizations (CRO’s)
4.3.1.4. Academic & Research Institutes
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Humanized Liver Mice Model Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
4.4.1.2. U.S. Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
4.4.1.3. U.S. Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
4.4.1.4. Canada Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
4.4.1.5. Canada Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
4.4.1.6. Canada Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Humanized Liver Mice Model Market Outlook, 2018 – 2031
5.1. Europe Humanized Liver Mice Model Market Outlook, by Model, Value (US$ Mn), 2018 – 2031
5.1.1. Key Highlights
5.1.1.1. uPA-SCID
5.1.1.2. FRG KO Mice
5.1.1.3. TK-NOG Mice
5.1.1.4. Other Models
5.2. Europe Humanized Liver Mice Model Market Outlook, by Application, Value (US$ Mn), 2018 – 2031
5.2.1. Key Highlights
5.2.1.1. Pharmacokinetics Studies
5.2.1.2. In-vivo Liver Toxicity Testing
5.2.1.3. Drug Metabolism Studies
5.2.1.4. Others
5.3. Europe Humanized Liver Mice Model Market Outlook, by End User, Value (US$ Mn), 2018 – 2031
5.3.1. Key Highlights
5.3.1.1. Pharmaceutical Companies
5.3.1.2. Biotechnology Companies
5.3.1.3. Contract Research Organizations (CRO’s)
5.3.1.4. Academic & Research Institutes
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Humanized Liver Mice Model Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
5.4.1. Key Highlights
5.4.1.1. Germany Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
5.4.1.2. Germany Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
5.4.1.3. Germany Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
5.4.1.4. U.K. Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
5.4.1.5. U.K. Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
5.4.1.6. U.K. Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
5.4.1.7. France Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
5.4.1.8. France Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
5.4.1.9. France Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
5.4.1.10. Italy Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
5.4.1.11. Italy Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
5.4.1.12. Italy Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
5.4.1.13. Turkey Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
5.4.1.14. Turkey Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
5.4.1.15. Turkey Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
5.4.1.16. Russia Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
5.4.1.17. Russia Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
5.4.1.18. Russia Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
5.4.1.19. Rest of Europe Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
5.4.1.20. Rest of Europe Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
5.4.1.21. Rest of Europe Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Humanized Liver Mice Model Market Outlook, 2018 – 2031
6.1. Asia Pacific Humanized Liver Mice Model Market Outlook, by Model, Value (US$ Mn), 2018 – 2031
6.1.1. Key Highlights
6.1.1.1. uPA-SCID
6.1.1.2. FRG KO Mice
6.1.1.3. TK-NOG Mice
6.1.1.4. Other Models
6.2. Asia Pacific Humanized Liver Mice Model Market Outlook, by Application, Value (US$ Mn), 2018 – 2031
6.2.1. Key Highlights
6.2.1.1. Pharmacokinetics Studies
6.2.1.2. In-vivo Liver Toxicity Testing
6.2.1.3. Drug Metabolism Studies
6.2.1.4. Others
6.3. Asia Pacific Humanized Liver Mice Model Market Outlook, by End User, Value (US$ Mn), 2018 – 2031
6.3.1. Key Highlights
6.3.1.1. Pharmaceutical Companies
6.3.1.2. Biotechnology Companies
6.3.1.3. Contract Research Organizations (CRO’s)
6.3.1.4. Academic & Research Institutes
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Humanized Liver Mice Model Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
6.4.1. Key Highlights
6.4.1.1. China Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
6.4.1.2. China Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
6.4.1.3. China Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
6.4.1.4. Japan Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
6.4.1.5. Japan Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
6.4.1.6. Japan Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
6.4.1.7. South Korea Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
6.4.1.8. South Korea Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
6.4.1.9. South Korea Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
6.4.1.10. India Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
6.4.1.11. India Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
6.4.1.12. India Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
6.4.1.13. Southeast Asia Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
6.4.1.14. Southeast Asia Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
6.4.1.15. Southeast Asia Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
6.4.1.16. Rest of Asia Pacific Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
6.4.1.17. Rest of Asia Pacific Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
6.4.1.18. Rest of Asia Pacific Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Humanized Liver Mice Model Market Outlook, 2018 – 2031
7.1. Latin America Humanized Liver Mice Model Market Outlook, by Model, Value (US$ Mn), 2018 – 2031
7.1.1. Key Highlights
7.1.1.1. uPA-SCID
7.1.1.2. FRG KO Mice
7.1.1.3. TK-NOG Mice
7.1.1.4. Other Models
7.2. Latin America Humanized Liver Mice Model Market Outlook, by Application, Value (US$ Mn), 2018 – 2031
7.2.1.1. Pharmacokinetics Studies
7.2.1.2. In-vivo Liver Toxicity Testing
7.2.1.3. Drug Metabolism Studies
7.2.1.4. Others
7.3. Latin America Humanized Liver Mice Model Market Outlook, by End User, Value (US$ Mn), 2018 – 2031
7.3.1. Key Highlights
7.3.1.1. Pharmaceutical Companies
7.3.1.2. Biotechnology Companies
7.3.1.3. Contract Research Organizations (CRO’s)
7.3.1.4. Academic & Research Institutes
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Humanized Liver Mice Model Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
7.4.1.2. Brazil Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
7.4.1.3. Brazil Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
7.4.1.4. Mexico Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
7.4.1.5. Mexico Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
7.4.1.6. Mexico Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
7.4.1.7. Argentina Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
7.4.1.8. Argentina Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
7.4.1.9. Argentina Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
7.4.1.10. Rest of Latin America Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
7.4.1.11. Rest of Latin America Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
7.4.1.12. Rest of Latin America Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Humanized Liver Mice Model Market Outlook, 2018 – 2031
8.1. Middle East & Africa Humanized Liver Mice Model Market Outlook, by Model, Value (US$ Mn), 2018 – 2031
8.1.1. Key Highlights
8.1.1.1. uPA-SCID
8.1.1.2. FRG KO Mice
8.1.1.3. TK-NOG Mice
8.1.1.4. Other Models
8.2. Middle East & Africa Humanized Liver Mice Model Market Outlook, by Application, Value (US$ Mn), 2018 – 2031
8.2.1. Key Highlights
8.2.1.1. Pharmacokinetics Studies
8.2.1.2. In-vivo Liver Toxicity Testing
8.2.1.3. Drug Metabolism Studies
8.2.1.4. Others
8.3. Middle East & Africa Humanized Liver Mice Model Market Outlook, by End User, Value (US$ Mn), 2018 – 2031
8.3.1. Key Highlights
8.3.1.1. Pharmaceutical Companies
8.3.1.2. Biotechnology Companies
8.3.1.3. Contract Research Organizations (CRO’s)
8.3.1.4. Academic & Research Institutes
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Humanized Liver Mice Model Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
8.4.1. Key Highlights
8.4.1.1. GCC Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
8.4.1.2. GCC Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
8.4.1.3. GCC Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
8.4.1.4. South Africa Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
8.4.1.5. South Africa Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
8.4.1.6. South Africa Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
8.4.1.7. Egypt Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
8.4.1.8. Egypt Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
8.4.1.9. Egypt Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
8.4.1.10. Nigeria Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
8.4.1.11. Nigeria Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
8.4.1.12. Nigeria Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
8.4.1.13. Rest of Middle East & Africa Humanized Liver Mice Model Market by Model, Value (US$ Mn), 2018 – 2031
8.4.1.14. Rest of Middle East & Africa Humanized Liver Mice Model Market by Application, Value (US$ Mn), 2018 – 2031
8.4.1.15. Rest of Middle East & Africa Humanized Liver Mice Model Market by End User, Value (US$ Mn), 2018 – 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By End User vs by Application Heat map
9.2. Manufacturer vs by Application Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Hera BioLabs
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Taconic Biosciences, Inc.
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Beijing Vitalstar Biotechnology Co., Ltd.
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Yecuris Corporation
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. PhoenixBio Group
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. In-Vivo Science Inc.
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. The Jackson Laboratory
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. University of Massachusetts Medical School(Mueller Lab)
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Oncodesign
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. University of Nebraska Medical Center
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings